Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)Product type:GuidanceProgramme:NICE guidelinePublished: 6 March 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Ruxolitinib for treating polycythaemia vera (TA921)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Voxelotor for treating sickle cell disease [ID1403]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 11 April 2024Expected publication date: 17 July 2024
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Avapritinib for treating advanced systemic mastocytosis ID3770Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 December 2024
Suspected sepsis: recognition, diagnosis and early managementStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 August 2025
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over TS ID 11956Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC